No Data
No Data
Northstrive Biosciences Inc. Advances Obesity Treatment Candidates EL-22 and EL-32 With FDA Pre-IND Meeting Preparation
Express News | Northstrive - Anticipates Type B Pre-Ind Meeting With FDA in Q2 2025
Express News | Pmgc Unit, Northstrive, Says Preparing for FDA Investigational New Drug Filing for El-22
Northstrive Biosciences, Inc., a Subsidiary of PMGC Holdings Inc., Reports Positive Updates for Obesity Drug Candidates Targeting Fat Loss and Muscle Preservation Used in Combination With GLP-1
PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc., Begins to Build Portfolio With Strategic Acquisition of Shares in U.S.-Focused Uranium Energy and Fire Prevention Technology Companies
PMGC Holdings' Northstrive Biosciences Initiates Study On EL-32 Alone And With Semaglutide For Obesity, Targeting Glycemic Control And Body Composition In Mice; Results Expected In 3-Months
Unlock the Full List
kingrotch : thank you for your work![pray 🙏](https://static.moomoo.com/nnq/emoji/static/image/img-apple-64/1f64f-1f3fb.png)
![pray 🙏](https://static.moomoo.com/nnq/emoji/static/image/img-apple-64/1f64f-1f3fb.png)
![pray 🙏](https://static.moomoo.com/nnq/emoji/static/image/img-apple-64/1f64f-1f3fb.png)
真名有晨 : Thank you very much
Please take care and rest.
iluvpoptarts : sry doc. I'm too busy counting the money your making me too look. muha
IamBadNewz : @Jaguar8 Been waiting (im)patiently for a pop on CGTX given the recent conference and news of insider buying but price hasn’t reacted. Your thoughts?
Jaguar8 OP IamBadNewz : You have to be patient
View more comments...